MESNA Injection for TMJ Internal Derangement

Tanta University

Status: Completed

Conditions: TMJ Disorder

Treatments: Drug: Arthrocentesis with ringer solution; Drug: Mesna Injection

Study type: Interventional

Funder types: Other

Identifiers

NCT05882604

#R-OS-4-23-3

Details and patient eligibility

About

The pathogenesis of temporomandibular disorders focusing on the biochemistry of the synovial fluid in various stages of temporomandibular joint disease. The role of inflammation has been investigated and proposed as an underlying mechanism of pain and dysfunction of temporomandibular joint. MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the disulfide bonds between polypeptide chains of mucus. The tissue distribution of MESNA is negligible, and the elimination of the substance is rapidly and completely achieved by kidney

Enrollment: 60 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with TMJ internal derangement with reduction

Exclusion criteria

• inflammatory or connective tissue disease
• autoimmune disease history
• neurologic problems

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Intra-articular injection with MESNA solution

Experimental group

Description:

1 ml of MESNA will be injected intra-articular

Treatment:

Drug: Mesna Injection

Arthrocentesis with ringer solution

Active Comparator group

Description:

ringer solution will be used for arthrocentesis

Treatment:

Drug: Arthrocentesis with ringer solution